Progress on ocular siRNA gene-silencing therapy and drug delivery systems

被引：36
作者：
Jiang, Jinjin [1 ,2 ]
Zhang, Xinru [1 ,2 ]
Tang, Yue [1 ,2 ]
Li, Shuhan [2 ]
Chen, Jing [2 ]
机构：
[1] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, 1 DongQing Rd, Guiyang 550014, Peoples R China
[2] China Pharmaceut Univ, Dept Pharm, 639 Longmian Ave, Nanjing 211198, Peoples R China
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2021年 / 35卷 / 01期
关键词：
age-related macular degeneration; glaucoma; RNA interference technology; siRNA drugs; non-viral vectors; ENDOTHELIAL GROWTH-FACTOR; BETA-ADRENERGIC RECEPTORS; VEGF SIRNA; POSTERIOR SEGMENT; POLYETHYLENIMINE NANOPARTICLES; INTRAVITREAL INJECTION; MACULAR DEGENERATION; NONVIRAL VECTORS; RNA INTERFERENCE; CLINICAL-TRIAL;
D O I：
10.1111/fcp.12561
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Age-related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non-viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene-silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non-viral vectors for siRNA drugs.
引用
收藏
页码：4 / 24
页数：21
相关论文
共 127 条
  • [1] Ocular neuroprotection by siRNA targeting caspase-2
    Ahmed, Z.
    Kalinski, H.
    Berry, M.
    Almasieh, M.
    Ashush, H.
    Slager, N.
    Brafman, A.
    Spivak, I.
    Prasad, N.
    Mett, I.
    Shalom, E.
    Alpert, E.
    Di Polo, A.
    Feinstein, E.
    Logan, A.
    [J]. CELL DEATH & DISEASE, 2011, 2 : e173 - e173
  • [2] Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
    Aleku, Manuela
    Schulz, Petra
    Keil, Oliver
    Santel, Ansgar
    Schaeper, Ute
    Dieckhoff, Britta
    Janke, Oliver
    Endruschat, Jens
    Durieux, Birgit
    Roeder, Nadine
    Loeffler, Kathrin
    Lange, Christian
    Fechtner, Melanie
    Moepert, Kristin
    Fisch, Gerald
    Dames, Sibylle
    Arnold, Wolfgang
    Jochims, Karin
    Giese, Klaus
    Wiedenmann, Bertram
    Scholz, Arne
    Kaufmann, Joerg
    [J]. CANCER RESEARCH, 2008, 68 (23) : 9788 - 9798
  • [3] Treatment of ocular disorders by gene therapy
    Angeles Solinis, M.
    del Pozo-Rodriguez, Ana
    Apaolaza, Paola S.
    Rodriguez-Gascon, Alicia
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 95 : 331 - 342
  • [4] Arranz-Romera A., 2018, J CONTROL RELEASE, V2019, P26
  • [5] Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
    Avery, Robert L.
    Castellarin, Alessandro A.
    Steinle, Nathan C.
    Dhoot, Dilsher S.
    Pieramici, Dante Joseph
    See, Robert
    Couvillion, Stephen
    Nasir, Ma'an A.
    Rabena, Melvin D.
    Le, Kha
    Maia, Mauricio
    Visich, Jennifer E.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (12) : 1636 - 1641
  • [6] Barar Jaleh, 2009, J Ophthalmic Vis Res, V4, P238
  • [7] Drug delivery to the eye: current trends and future perspectives
    Behar-Cohen, Francine
    [J]. THERAPEUTIC DELIVERY, 2012, 3 (10) : 1135 - 1137
  • [8] Non-viral ocular gene therapy: Potential ocular therapeutic avenues
    Bloquel, C.
    Bourges, J. L.
    Touchard, E.
    Berdugo, M.
    BenEzra, D.
    Behar-Cohen, F.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (11) : 1224 - 1242
  • [9] Intraocular implants for extended drug delivery: Therapeutic applications
    Bourges, J. L.
    Bloquel, C.
    Thomas, A.
    Froussart, F.
    Bochot, A.
    Azan, F.
    Gurny, R.
    BenEzra, D.
    Behar-Cohen, F.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (11) : 1182 - 1202
  • [10] Inhibition of oxygen-induced retinopathy in RTP801-deficient mice
    Brafman, A
    Mett, I
    Shafir, M
    Gottlieb, H
    Damari, G
    Gozlan-Kelner, S
    Vishnevskia-Dai, V
    Skaliter, R
    Einat, P
    Faerman, A
    Feinstein, E
    Shoshani, T
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (10) : 3796 - 3805
12345678910